Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why EU Must Reform Regulation And Funding For Life-Saving Cancer Biomarker Tests

Executive Summary

UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?

You may also be interested in...

MedTech Europe IVDR Impact Report: The Good, The Bad And The Ugly

The outcome of a survey by trade association MedTech Europe shows that while more than 90% of companies benefited from the extension of IVDR transition deadlines, significant issues remain that could see many diagnostics disappear from the market.

When Is An IVD A CDx? EU IVDR Guidance Updated To Include Flowchart

The EU Medical Device Coordination Group has issued a second revision to its guidance document on classification rules for in vitro diagnostics under the new regulation. The addition of a flowchart to determine when an IVD is a companion diagnostic is one key change.

EU IVDR Milestone: Cancer Biomarker Test First To Get A Companion Diagnostic CE Marking

A major milestone has been reached in the EU after a cancer biomarker assay became the first product to receive a companion diagnostic certificate in the context of the EU In Vitro Diagnostic Regulation.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts